| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
jill_glasspool-malone [2023/03/05 07:35]
liam [Career] | jill_glasspool-malone [2023/03/05 19:15] (current)
liam [Career] |
|---|
| === Gene Delivery Alliance === | === Gene Delivery Alliance === |
| |
| On April 19, 2001, Glasspool-Malone founded the [[pharmaceutical_companies:Gene Delivery Alliance]].((Delaware Department of State Division of Corporations. (2019, August 19). //GENE DELIVERY ALLIANCE, INC.// OpenCorporates. https://archive.ph/ve1EU)) In 2002, she published a paper titled //[[https://www.sciencedirect.com/science/article/abs/pii/S0076687902460491|Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields]]// with [[Robert Malone]] on which she lists Gene Delivery Alliance as her affiliation.((Glasspool-Malone, J., & Malone, R. W. (2002). //[4] Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields.// Methods in Enzymology, 72–91. [[https://www.sciencedirect.com/science/article/abs/pii/S0076687902460491|https://doi.org/10.1016/s0076-6879(02)46049-1]])) | On April 19, 2001, Glasspool-Malone founded the [[pharmaceutical_companies:Gene Delivery Alliance]], and became CEO of [[Robert Malone MD, LLC]] in August 2001.((Delaware Department of State Division of Corporations. (2019, August 19). //GENE DELIVERY ALLIANCE, INC.// OpenCorporates. https://archive.ph/ve1EU)) From September 2001 to June 2005, she studied Public Policy at the [[Union Institute & University]] with a specialization in biotechnology. |
| | |
| | In 2002, she published a paper titled //[[https://www.sciencedirect.com/science/article/abs/pii/S0076687902460491|Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields]]// with [[Robert Malone]] on which she lists Gene Delivery Alliance as her affiliation.((Glasspool-Malone, J., & Malone, R. W. (2002). //[4] Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields.// Methods in Enzymology, 72–91. [[https://www.sciencedirect.com/science/article/abs/pii/S0076687902460491|https://doi.org/10.1016/s0076-6879(02)46049-1]])) |
| |
| She and Robert both received postgraduate training as a [[Harvard Medical School]] Global Clinical Scholar in 2015-2016.((//Dr. Jill Glasspool | Atheric Pharmaceutical | United States of America.// OMICS International. Retrieved March 5, 2023, from http://archive.today/2023.03.05-034708/https://biography.omicsonline.org/united-states-of-america/atheric-pharmaceutical/dr-jill-glasspool-524863)) | She and Robert both received postgraduate training as a [[Harvard Medical School]] Global Clinical Scholar in 2015-2016.((//Dr. Jill Glasspool | Atheric Pharmaceutical | United States of America.// OMICS International. Retrieved March 5, 2023, from http://archive.today/2023.03.05-034708/https://biography.omicsonline.org/united-states-of-america/atheric-pharmaceutical/dr-jill-glasspool-524863)) |
| |
| On May 17, 2021, Glasspool-Malone posted two back-to-back comments on an [[IPWatchdog]] article titled "The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I". The first comment read, "Robert Malone and I have a patent that included RNA vaccination, which expired in 2017, but it is interesting because many of the patents listed above and issued prior to 2017 – claim nasal and mucosal routes." She included the patent, titled "[[https://archive.ph/y6YEh|DNA vaccines for eliciting a mucosal immune response]]", assigned to the [[University of Maryland]]. The second comment, posted only four minutes later, read, "As Robert Malone clearly invented mRNA vaccines while at the Salk and Vical, it is interesting that there is not mention of his work?" followed by a series of publications and patents.((Shores, D., Haversack, D., & Storaska, A. J. (2021, April 11). //The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic –Part I.// IPWatchdog. http://archive.today/2023.03.04-185835/https://ipwatchdog.com/2021/04/11/mrna-ip-competitive-landscape-one-year-covid-19-pandemic-part/id=132130/)) | On May 17, 2021, Glasspool-Malone posted two back-to-back comments on an [[IPWatchdog]] article titled "The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I". The first comment read, "Robert Malone and I have a patent that included RNA vaccination, which expired in 2017, but it is interesting because many of the patents listed above and issued prior to 2017 – claim nasal and mucosal routes." She included the patent, titled "[[https://archive.ph/y6YEh|DNA vaccines for eliciting a mucosal immune response]]", assigned to the [[University of Maryland]]. The second comment, posted only four minutes later, read, "As Robert Malone clearly invented mRNA vaccines while at the Salk and Vical, it is interesting that there is not mention of his work?" followed by a series of publications and patents.((Shores, D., Haversack, D., & Storaska, A. J. (2021, April 11). //The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic –Part I.// IPWatchdog. http://archive.today/2023.03.04-185835/https://ipwatchdog.com/2021/04/11/mrna-ip-competitive-landscape-one-year-covid-19-pandemic-part/id=132130/)) |
| | |
| | In June 2021, Glasspool-Malone published a short essay titled "A Scientific Education: The Early Discoveries of RNA and DNA Vaccination" in which she articulated her perspective on Malone's career as it relates to the invention of [[mRNA vaccines]] and [[DNA vaccines]].((Glasspool-Malone, J. (2021, June). //A Scientific Education: The Early Discoveries of RNA and DNA Vaccination.// Squarespace. https://web.archive.org/web/20230120032719/https://static1.squarespace.com/static/550b0ac4e4b0c16cdea1b084/t/60b62e4f1dcb1f52ad2d4c0c/1622552143483/Jill%27s+letter+about+RNA+vaccination+generic+v5+June2021.pdf)) |
| |
| ===== Publications ===== | ===== Publications ===== |
